delta 777

Hoping Against Hope for Wyeth / Elan Alzheimer Dug

"Human beings are the only animals that really seem to get Alzheimer's, and that's made it a ferocious therapeutic area to work in"
perhaps not quite true--it appears that vervet monkeys also develop a condition as they get old that is very close to a human form of Alzheimer's. This is species specific, as rhesus monkeys do not develop this. Vervets have some other characteristics that are particularly relevant to humans.
www.dana.org/news/feat...
pin.primate.wisc.edu/f... (see special notes sections)

J&J Comes Riding to Elan's Rescue

Elan has been suffering a horrible partnership in Tysabri with Biogen, who may have been sandbagging Tysabri to promote their competing drug Avonex, meanwhile salivating at the prospect of being able to make a hostile move to buy Elan's interest in Tysabri for pennies, against a very weak Elan in 2010 when standoff clauses in their partnership expire.
Wyeth/AHP is potentially also a wolf in sheeps clothing with respect to their bapineuzumab partnership with Elan (anyone remember Immunex?-R.I.P.) and when Pfizer acquires Wyeth, this cabal can not be anticipated to behave like angels in their partnership behavior
Even more significant than the much needed direct financial boost that Elan has been needing to set up, JNJ has both sufficient clout and a big enough legal department to deal with the pack of hyenas that have been circling to pick Elan's bones as well as an excellent background to insure that bapineuzumab will be properly guidedto market, even though they do not (nominally) have control of this drug. The JNJ/Elan arrangement also is a great protection of other Elan pipeline drugs against the type of manipulation that Tysabri has suffered at the hands of Biogen. JNJ has a pretty good rep as an ethical outfit.
Somewhat disturbing is key scientists Selkoe and Bloom stepping down from the Elan Board of Directors.

Who Is the Worst Biotech CEO?

recognition and acceptance Fuersteins yellow journalism and narcissism in considering himself the Nobel Committee of biotech management evaluation is extremely dangerous, whereby on the basis of promulgation of one person's irresponsible voice by an increasingly rabid media, this can exert a substantial and disproportionate effect on an equity of the nature that should even warrant criminal investigation.

Likewise, you should be thoroughly ashamed of yourself for promulgating this kind charade.....it speaks to your own competence.

Elan, Wyeth Take an Inside-Out Approach to Alzheimer's Vaccine

jarcom--you say "An alzheimer vacine....simply panovian. AHP used to be smarter than to go for such stuff."-----are you perhaps suggesting that AHP was "smarter" in its fen/phen days????

Elan, Wyeth Take an Inside-Out Approach to Alzheimer's Vaccine

again, Here Derek seems to share a common confusion with respect to Elan's Alzheimer's pipeline....Right now their prime focus is on an antibody (not a vaccine) therapy identified as AAB-001 (Bapineuzimab), which anticipates important PII result announcement very soon, and full PII info at ICAD on July 30..PIII for AAB-001 has already started... Although AAB-001 is an immunologic approach, it is distinctly different and not to be confused with ACC-001 which is an antigen, or vaccine.. Elan has several other extremely promising Alzheimer's drugs in its pipeline, as well as the highly effective multiple sclerosis drug Tysabri....Elan is primarily a research biotech, and commonly partners with companies better equipped for large scale manufacturing. (which arrangementsd also, because of careful poison pill agreements, protect against easy hostile take-over)....There is a very active InvestorVillage message board with quite a few brilliant and very knowledgeable posters on Elan (significant posts can be roughly presorted based based on number of recs, then following the thread): www.investorvillage.co...